Cerebral venous sinus thrombosis in a 30-year-old woman on medroxyprogesterone acetate: a case report

Gloire Chubaka Magala; Fiacre Delors Offoumou; Roseline Mohou Felandine Kouassi; Cédric Valery Kadjo; Marceline Sifa Balungwe; Arlette Désirée Aka; Muriel Amon-Tanoh; Constance Yapo-Ehounoud; Abel Christian Tanoh; Mariam Doumbia-Ouattara; Évelyne Aka-Anghui Diarra; Berthe Assi

doi:10.18203/2320-1770.ijrcog20243959

Authors

Gloire Chubaka Magala Neurology Department, Cocody Teaching Hospital, Abidjan, Ivory Coast
Fiacre Delors Offoumou Neurology Department, Cocody Teaching Hospital, Abidjan, Ivory Coast
Roseline Mohou Felandine Kouassi Neurology Department, Cocody Teaching Hospital, Abidjan, Ivory Coast
Cédric Valery Kadjo Neurology Department, Cocody Teaching Hospital, Abidjan, Ivory Coast
Marceline Sifa Balungwe Gynecology and Obstetrics Department, Institute Supérieur De Technique Médicale, Nyangezi, South Kivu, DRC
Arlette Désirée Aka Neurology Department, Cocody Teaching Hospital, Abidjan, Ivory Coast
Muriel Amon-Tanoh Neurology Department, Cocody Teaching Hospital, Abidjan, Ivory Coast
Constance Yapo-Ehounoud Neurology Department, Cocody Teaching Hospital, Abidjan, Ivory Coast
Abel Christian Tanoh Neurology Department, Cocody Teaching Hospital, Abidjan, Ivory Coast
Mariam Doumbia-Ouattara Neurology Department, Yopougon Teaching Hospital, Abidjan, Ivory Coast
Évelyne Aka-Anghui Diarra Neurology Department, Cocody Teaching Hospital, Abidjan, Ivory Coast
Berthe Assi Neurology Department, Cocody Teaching Hospital, Abidjan, Ivory Coast

DOI:

https://doi.org/10.18203/2320-1770.ijrcog20243959

Keywords:

Cerebral venous sinus thrombosis, Progestative contraception, Depot medroxyprogesterone acetate, Case report, Ivory coast

Abstract

About 80% of patients diagnosed with cerebral venous sinus thrombosis (CVST) exhibit a prothrombotic risk factor or an identifiable direct cause. The use of combined oral contraceptives (COC) is well recognized as a significant risk factor among women. Furthermore, it has been demonstrated that progestins, whether administered alone or in conjunction with ethinyl estradiol, are also linked to an increased risk of venous thrombosis. This study presents the first documented case in Ivory Coast of cerebral venous thrombosis in a young woman without any other identifiable prothrombotic risk factors, who was receiving depot medroxyprogesterone acetate (DMPA), a long-acting injectable progestin contraceptive. The patient, a 30-year-old right-handed female, was utilizing a progestin-based contraceptive method (medroxyprogesterone acetate, PROVERA DEPO) administered quarterly. At the time of her admission to the neurology department, she was receiving her second injection and presented with recent, atypical headaches that escalated rapidly. The neurological examination upon admission revealed signs of intracranial hypertension and a spastic pyramidal syndrome affecting the left side. Neuroimaging studies, including CT and MRI, identified cerebral venous thromboses in the right sinus and the superior sagittal sinus. Further investigations did not reveal any abnormalities associated with thrombophilia, autoimmune disorders, neoplasms, or infections. The patient received anticoagulant therapy at an effective dosage for a duration of six months, resulting in a reduction of headaches and the resolution of motor deficits. Any neurological event in a patient receiving Medroxyprogesterone Acetate, necessitates a neuroimaging evaluation to rule out the presence of CVST.

Metrics

Metrics Loading ...

References

Khan MW, Zeeshan HM, Iqbal S. Clinical profile and prognosis of cerebral venous sinus thrombosis. Cureus. 2020;12(12).

[2Amoozegar F, Ronksley PE, Sauve R, Menon BK. Hormonal contraceptives and cerebral venous thrombosis risk: a systematic review and meta-analysis. Frontiers in Neurol. 2015;6:7.

Baduro Y, Ferro JM. Cerebral venous thrombosis in sub-Saharan Africa: a systematic review. Journal of Stroke and Cerebrovascular Diseases. 2021;30(6):105712.

Rajput R, Dhuan J, Agarwal S, Gahlaut PS. Central venous sinus thrombosis in a young woman taking norethindrone acetate for dysfunctional uterine bleeding: case report and review of literature. J Obstet and Gynaecol Canada. 2008;30(8):680-3.

de Freitas GR, Bogousslavsky J. Risk factors of cerebral vein and sinus thrombosis. Handbook on cerebral venous thrombosis. 2008;23:23-54.

Krishnan A, Karnad DR, Limaye U, Siddharth W. Cerebral venous and dural sinus thrombosis in severe falciparum malaria. J Infec. 2004;48(1):86-90.

Krishnan A, Karnad DR, Limaye U, Siddharth W. Cerebral venous and dural sinus thrombosis in severe falciparum malaria. J of infection. 2004;48(1):86-90.

AVan Hylckama Vlieg A, Helmerhorst FM, Rosendaal FR. The risk of deep venous thrombosis associated with injectable depot–medroxyprogesterone acetate contraceptives or a levonorgestrel intrauterine device. Arteriosclerosis, thrombosis, and vascular biology. 2010;30(11):2297-300.

van Hylckama Vlieg A, Helmerhorst FM, Vandenbroucke JP, Doggen CJ, Rosendaal FR. The venous thrombotic risk of oral contraceptives, effects of oestrogen dose and progestogen type: results of the MEGA case-control study. Bmj. 2009;339.

Lidegaard Ø, Løkkegaard E, Svendsen AL, Agger C. Hormonal contraception and risk of venous thromboembolism: national follow-up study. BMJ. 2009;13:339.

Poulter N, Chang C, Farley T. Cardiovascular disease and the use of oral and injectable progestogen-only contraceptives, as well as combined injectable contraceptives. Findings from an international, multicenter, case-control study. World Health Organization Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception. Contraception. 1998;57(5):315-324.

Hitosugi MA, Kitamura OS, Takatsu AK, Watanabe KO, Kan SH. A case of dural sinus thrombosis during the medication of medroxyprogesterone acetate. Nihon Hoigaku Zasshi. The Japanese J of Legal Med. 1997;51(6):452-6.

Bahall M, Santlal M. Norethisterone enanthate-induced cerebral venous sinus thrombosis (CVST). Case Reports. 2017 Nov 14;2017:20.

Ramya T, Prakash B, Devi B. Norethisterone induced cerebral venous sinus thrombosis (CVST): a rare case report and review of literature. International Journal of Reproduction, Contraception, Obstetrics and Gynecology. 2014s;3(1):231-6.

Otite FO, Patel S, Sharma R, Khandwala P, Desai D, Latorre JG, Akano EO, Anikpezie N, Izzy S, Malik AM, Yavagal D. Trends in incidence and epidemiologic characteristics of cerebral venous thrombosis in the United States. Neurology. 2020;95(16):200-13.

Dentali F, Gianni M, Crowther MA, Ageno W. Natural history of cerebral vein thrombosis: a systematic review. Blood. 2006;108(4):1129-34.

Magala C. Cerebral venous thrombosis as an uncommon etiology of spontaneous subarachnoid hemorrhage: Case report », J Clin Images Med Case. 2018;5(7):3209.

[Napon C, Diallo O, Kanyala E, Kabore J. Les thromboses veineuses cérébrales en milieu hospitalier à Ouagadougou (Burkina Faso). Revue neurologique. 2010;166(4):433-7.

Kombate D, Assogba K, Kumako V, Diatewa J, Apetse K, Guinhouya KM, et al. Prevalence hospitaliere et facteurs de risque de la thrombose veineuse cerebrale au Togo. African J Neurol Sci. 2017;36(1):23-9.

Koupaei SR, Ziaee M, Baharvahdat H, Ahmadi Z, Deluee MT, Kakhki BR, et al. An Epidemiological Investigation on Patients with Non-traumatic Subarachnoid Hemorrhage from 2010 to 2020. Bulletin of Emergency & Trauma. 2024;12(1):35.

Bienfait H, Gijtenbeek J, van den Bent M, de Bruin H, Voogt P, Pillay M. Cerebral venous and sinus thrombosis with cerebrospinal fluid circulation block after the first methotrexate administration by lumbar puncture. Neuroradiology. 2002:929-32.

[Karam C, Koussa S. Cerebral dural sinus thrombosis following cisplatin chemotherapy. Journal of Clinical Neuroscience. 2008;15(11):1274-5.

Lidegaard Ø, Nielsen LH, Skovlund CW, Løkkegaard E. Venous thrombosis in users of non-oral hormonal contraception: follow-up study, Denmark 2001-10. Bmj. 2012;10:344.

Ulivi L, Squitieri M, Cohen H, Cowley P, Werring DJ. Cerebral venous thrombosis: a practical guide. Practical neurology. 2020;20(5):356-67.

[Guenther G, Arauz A. Trombosis venosa cerebral: aspectos actuales del diagnóstico y tratamiento. Neurología. 2011;26(8):488-98.

Smith E, Kumar V. BET 1: Does a normal D-dimer rule out cerebral venous sinus thrombosis (CVST)?. Emergency Medicine Journal: EMJ. 2018;35(6):396.

Saposnik G, Bushnell C, Coutinho JM, Field TS, Furie KL, Galadanci N, Kam W, Kirkham FC, McNair ND, Singhal AB, Thijs V. Diagnosis and management of cerebral venous thrombosis: a Scientific Statement from the American Heart Association. Stroke. 2024;55(3):77-90.

Field TS, Dizonno V, Almekhlafi MA, Bala F, Alhabli I, Wong H, et al. Study of rivaroxaban for cerebral venous thrombosis: a randomized controlled feasibility trial comparing anticoagulation with rivaroxaban to standard-of-Care in Symptomatic Cerebral Venous Thrombosis. Stroke. 2023;54(11):2724-36.

Miranda. The benefit of EXtending oral antiCOAgulation treatment (EXCOA) after acute cerebral vein thrombosis (CVT): EXCOA-CVT cluster randomized trial protocol. Int J Stroke. 2018;13(7):771‑4.